Tag:
MDV3100
Latest Headlines
Latest Headlines
High-profile investigator tapped to lead $10M prostate cancer program
Charles Sawyers has been tapped to help lead a $10 million effort to test personalized treatments for prostate cancer.
UPDATED: Aragon raises $42M for closely-watched prostate cancer drug
Now that San Diego-based Aragon Pharmaceuticals has wrapped its early-stage work on their anti-androgen prostate cancer drug ARN-509 with some encouraging indications of its impact on tumors, the...
Surveyed docs see need for new prostate-cancer meds, Medivation says
Medivation ($MDVN), which is developing a new treatment for prostate cancer, said a European survey found that doctors see a need for new treatments that extend patients' lives, with 85% of...
Medivation surges as rivals aim at fast-changing prostate cancer market
Shares of Medivation ( $MDVN ) jumped 17% today after the drug developer confirmed some promising Phase III data on the closely-watched prostate cancer therapy MDV3100 and added some reassuring numbers
Pfizer writes off $725M Dimebon pact after final Phase III failure
The last flickering hope that Medivation's Dimebon could help Alzheimer's disease patients has just been extinguished. The biotech announced this morning that a 12-month study of the drug failed to
UPDATED: Medivation shares skyrocket on positive PhIII prostate cancer data
Medivation is reporting a promising set of late-stage data for MDV3100 this morning, offering some hard proof that the drug compares favorably with the newly-approved Zytiga for improving overall
Medivation chief amps up rhetoric on Ph3 prostate cancer drug
With much of his company's future hinging on its experimental prostate cancer drug, Medivation ( $MDVN ) CEO David Hung listed the ways the Phase III treatment could be better than rivals, taking dead
Medivation prostate cancer drug back in the spotlight
In a review of the pricey new prostate cancer treatments hitting the market, Reuters directed its spotlight to Medivation's MDV3100, noting its closely watched status as the biotech readies a crucial
Abiraterone vs. MDV3100: A prostate cancer drug showdown
Medivation CEO David Hung is a persuasive individual. He has negotiated some of the most lucrative drug development collaborations in biotechnology. Pfizer's $225 million upfront for Dimebon remains
Medivation forges $765M cancer deal with Astellas
In just the latest sign of just how hot new cancer drugs have become, San Francisco-based Medivation garnered a $110 million upfront payment and a milestone package of $655 million from Astellas for
